Abstract
Introduction
Pituitary adenomas (PAs) are benign neoplasms of the pituitary gland, comprising approximately 8% of all primary brain and central nervous system tumors 1 . In a recent
Finnish study, approximately 36% of all PAs were clinically nonfunctioning pituitary adenomas (NFPAs), of which 82% were macroadenomas 2 . In contrast to hormonesecreting PAs, NFPAs are not characterized by hormonal overproduction but usually present with symptoms and signs of tumor mass effects, such as visual field defects and hypopituitarism, often including growth hormone deficiency (GHD) 3 .
The primary treatment of choice for NFPAs is pituitary surgery, which aims at complete tumor removal or debulking and relieve of tumoral mass effects on adjacent structures, especially the optic chiasm. Losa et al. described that complete surgical removal may be achieved in more than 50% of the cases, although tumors may recur afterwards 4 . In case of substantial residual tumor or tumor progression, adjuvant radiotherapy is often advocated 5 . Although beneficial effects of radiotherapy in terms of local tumor control have been described, its use in the management of NFPAs, especially prophylactically, is still a subject of debate because concerns remain about potential long-term side effects 3, [6] [7] [8] [9] [10] [11] . The most common observed side effect is the gradual development of hypopituitarism 12, 13 . However, concerns 14 . Although some studies confirm this potential relationship between pituitary irradiation and cerebrovascular events (CVEs) and CVE-related deaths 8, 14, 15 , others found no or less clear associations 16, 17 .
Conflicting results have also been reported with regard to the development of secondary intracranial tumors following pituitary irradiation. Although some studies showed increased risks of secondary intracranial tumors 18, 19 , other investigators found no firm indications for an increased risk [20] [21] [22] .
Because most of these previous studies included patients with various types of
PAs, interpretation of the results for NFPA patients specifically is complicated. Also, findings in PA patients were usually, although not in all cases, compared to those in a normal reference population, in whom other potentially contributing factors related to the PAs and their treatments are not applicable.
Therefore, we aimed to investigate the risk of CVEs, secondary intracranial tumors, and mortality in a large cohort of patients with a NFPA, using data from the Dutch 4 National Registry of Growth Hormone Treatment in Adults, a nationwide long-term surveillance study in severe GHD adult patients, thereby comparing NFPA patients who received radiotherapy with those who did not receive radiotherapy.
Methods

Study population
The Dutch National Registry of Growth Hormone Treatment in Adults was initiated in 1998 by the Dutch Ministry of Health in order to gain more insight into the long-term efficacy, safety and costs of growth hormone replacement therapy (GH-RT) in GHD adults. From that time on, reimbursement of GH-RT costs was linked to approval of the indication, severe GHD, by an independent board of endocrinologists as well as entry of anonymous patient data into the registry. All patients were informed by their attending physician. Severe GHD was diagnosed according to the Growth Hormone
Research Society consensus guidelines 23 . Data collection, patient characteristics and test procedures have previously been described in more detail 24 . The registry contains not only the follow-up data of the majority of GHD patients who were treated with GH-RT, but also of GHD patients in whom GH-RT was not commenced or (temporarily) discontinued for various reasons. Reasons for not commencing with or discontinuation of GH-RT have been described previously 25 . Until data closure in 2009, a total of 2891 severe GHD adults were entered into the nationwide database.
For the present study, severe GHD patients with a NFPA were selected (n = 887).
Patients from whom data could not be collected by a trained monitor due to application shortly before closure of the database in 2009, leading to insufficient follow-up, were excluded (n = 75). In addition, patients with inconclusive data on whether they had received pituitary radiotherapy (n = 6) were also excluded. Compared to those included in the study, excluded patients had a similar age at diagnosis of the NFPA, gender and onset of GHD.
Measurements
The data of all registered patients were collected (bi-) annually from medical records by specially trained monitors from the start of enrollment in the registry. When GH-RT had already been started before the first monitor visit, data were retrospectively retrieved. Collected data were checked for accuracy both before and after entry into the database. Also, in approximately 10% of the patients data were collected twice by different monitors as an internal quality control.
4
The diagnosis of NFPA, made at the discretion of the attending physician, was verified at entry into the database, according to the collected data. Central Bureau of Statistics, as described previously 25 .
Data concerning the treatment of the NFPAs, such as number, type, and timing of surgical procedures and radiotherapy, were also collected.
The growth hormone (GH) dose was titrated on an individual basis by the attending physician with the purpose of achieving and maintaining age-and gender-specific 
Statistical analysis
Continuous variables were expressed as either mean (SD) or median (range), whereas categorical variables were expressed as number (percentage). Parametric or nonparametric tests were used when appropriate. Kaplan-Meier survival curves were obtained to estimate the cumulative incidence of CVE in irradiated (IRR) and nonirradiated (non-IRR) patients, starting from the date of radiotherapy or diagnosis, respectively.
Cox proportional hazard analyses were used to study the association between radiotherapy and mortality risk and the risk of developing a CVE, respectively. Time was was measured from the first date of radiotherapy for the IRR-group and from the date of diagnosis of the NFPA for the non-IRR group, until date of death or last follow-up in the mortality analyses. In the CVE analyses, time ended at the date of first CVE, death or last follow-up, whichever occurred first. Assumptions of proportional hazards were tested by log-minus-log plots and interaction terms. To examine relevant 4 confounding, potentially influencing variables were added separately to the age-and gender-adjusted models. Variables that gave a change in the regression coefficient of > 10% were included in the model. Potentially confounding variables that were evaluated were GH-RT (yes or no), extension of pituitary deficiency (isolated GHD or multiple pituitary hormone deficiencies) and pituitary surgery (yes or no). In addition, adrenocorticotropic hormone (ACTH) insufficiency was also evaluated in the mortality analyses, whereas a history of CVE (unknown in n = 8) was also considered in the CVE analyses. All continuous variables were individually checked for linearity with the outcome variables and in case of nonlinearity divided in categories. Potential effect modification by gender was examined by adding an interaction term to the fully adjusted model. In case of a value of p < 0.10, analyses were presented in stratified groups.
Sensitivity analyses were performed in the fully adjusted model for the risk of developing CVE by excluding users (current or former) of anticoagulant or antiplatelet medication separately.
Due to the low number of events, the occurrence of secondary intracranial tumors is presented descriptively.
All statistical analyses were performed using the statistical software package IBM SPSS Statistics version 20. Two-sided values of p ≤ 0.05 were considered significant.
Results
Patient characteristics
A total of 806 patients, 313 (38.8%) females, with a mean age at the time of NFPA diagnosis of 48.3 (13.3) years, were included in the study. Almost all patients (95.5%) were treated with GH-RT, for a median period of 5.2 (0.03 -20.2) years.
The characteristics of IRR and non-IRR patients are shown in table 1. Most IRR patients (63.8%) were treated with conventional radiotherapy, whereas a minority (5.9%) received stereotactic radiotherapy. In the remaining patients, data on radiotherapy modality were not available. The mean radiation dose, which was unknown in 104 patients, was 46.2 (6.1) Gray. Six patients (1.3%) were treated twice with radiotherapy.
The median follow-up time for the entire cohort was 10.0 (0.1 -54.5) years. Median follow-up was 6.6 (0.5 -48.8) years for non-IRR patients and 12.7 (0.1 -54.5) years for IRR patients (p < 0.001). To analyze the association between radiotherapy and the risk of developing CVE, Cox proportional hazard analysis was used (table 3) . The analyses were stratified for gender because a significant interaction between radiotherapy and gender was observed (p = 0.02). Although several potential confounders were tested (GH-RT, extension of pituitary deficiency, pituitary surgery and history of CVE), age was found to be the only relevant confounder. In both the crude and the adjusted model, 
Mortality
In the total study population, 54 (6.7%) deaths, at a mean age of 68.4 (10.2) years, were observed. Median time between NFPA diagnosis and death was 11.8 (0.6 -54.5) years and 32 (59.3%) patients were males.
Of the 69 patients who developed a CVE during follow-up, 17 (24.6%) died, due to a CVA in 6 (35.4%) cases. Two of the seven (40%) patients with a secondary intracranial neoplasm, both with a glioma, died 2 and 6 months, respectively, after the second tumor diagnosis. Of all deceased patients, 32 (59.3%) had received radiotherapy.
In the Cox proportional hazard analyses on the association between radiotherapy and mortality risk no significant interaction with gender was found. After adjustment 
Discussion
To our knowledge, this is the largest cohort of NFPA patients in which the occurrence of CVEs, secondary intracranial tumors, and mortality was examined and compared between IRR and non-IRR patients. IRR men had a threefold increased risk of patients. However, the number of strokes in the total study population, 25 (5.4%),
was relatively low, which may have limited the ability to detect differences. Compared with the expected number of strokes in a Dutch reference population, the incidence in PA patients was increased 16 . Similarly, two other studies found increased incidences of cerebrovascular disease in IRR PA patients compared to a normal reference population 8, 14 , whereas in another early study, this was not observed 26 .
Except for the study by Sattler et al., all of these studies compared the CVE incidence in IRR PA patients with the incidence in a normal reference population 8, 14, 16, 26 .
Comparison with non-IRR PA patients may be more informative because in that way potential disease-related factors apply to both groups. Another difference between previous studies and the present study is the inclusion of different types of PAs. This may have influenced the results because GH-producing PAs, for instance, have been associated with an increased risk of cerebrovascular diseases 14, 15 .
In our study, an increased CVE risk was observed only in IRR men. Gender differences have also been reported by others, but notably with poorer outcomes for women 8, 14, 15, 17 . Gonadal insufficiency and (inadequate) hormonal replacement therapy have been proposed as possible contributing factors to explain the differences between the two genders 17, 27 . Although ACTH insufficiency occurred more often in IRR patients than in non-IRR patients in our study, the percentage of patients receiving gonadal replacement therapy was similar in both groups. Possibly, due to the low occurrence of CVEs in women the power to detect an association was too low. Interestingly, in 4 a previous study from our registry regarding GH-RT and mortality, mortality due to cardiovascular diseases was increased in women but not in men 25 . However, mortality due to CVA was not significantly different between the two genders 25 .
In a recent systematic review, an increased CVE risk following radiotherapy for various types of head or neck cancer was demonstrated, which is in line with our results 28 . However, data regarding possible underlying pathological mechanisms are scarce. A possible mechanism is the directly damaging effect of radiation to the cerebral vasculature [28] [29] [30] , which may result in the development of clinically significant stenosis 28 .
Hypopituitarism, especially GHD, has been associated with an increase in cardiovascular risk factors 31 and has therefore been proposed as another contributing factor 17 . In patients with hypopituitarism, increased cerebrovascular mortality has been described 27, 32 . However, the influence of radiotherapy in this relation was not a relevant confounder either, which suggests that GH-RT did not substantially contribute to the increased CVE risk in IRR men in the present study, even though the duration of GH-RT tended to be longer in men who developed a CVE compared with those who did not.
Another study reported that the extent of pituitary surgery (macroscopic or biopsy/none) and higher radiotherapy dose were possible risk factors for CVAs 14 .
In our study, pituitary surgery did not emerge as a relevant factor in the analyses.
Although our radiation dose data should be interpreted with caution, doses did not significantly differ between patients who did and did not develop a CVE. This is in accordance with the study by Erfurth et al., in which several radiation parameters were not significantly associated with cerebrovascular death 17 .
Whether radiotherapy induces secondary intracranial tumor formation in PA patients is still a matter of discussion. Two studies, with relatively few observed cases, found RRs of 10.5 (95% confidence interval (CI), 4.3 -16.7) and 16 (95% CI, 4.4 -41),
respectively, in PA patients in comparison with a reference population 18, 19 . Another study reported a standard incidence ratio of 5.2 (95% CI, 1.9 -11.31) 33 . However, intracranial tumors may be detected earlier in PA patients than in persons from 4 a normal population because PA patients are subject to close follow-up, including regular brain imaging.
In the present study, no firm indications were observed for an increased risk of secondary intracranial tumors. These results are in line with other published series 20-22 .
Similar to other studies [18] [19] [20] 22, 33 , meningiomas and gliomas were the most frequently encountered secondary intracranial tumors. It has been suggested that meningiomas tend to develop later after radiotherapy than gliomas and that they may occur as late as 30 years after radiotherapy 19, 34 . In the present study, a meningioma was diagnosed in one IRR patient 42 years after the first radiotherapy. However, in another IRR patient a meningioma was found within 1 year after radiotherapy, which therefore questions its relationship with the radiotherapy. In the one IRR patient who developed a glioma, the diagnose was made 12 years after radiotherapy, which is in line with the latency period of 8 -15 years for gliomas reported by Tsang et al. 18 .
Except for one patient who was irradiated twice, the radiation dose did not differ between patients who did and did not develop a secondary intracranial tumor.
An increased risk of meningiomas with higher radiation doses has been described 35 .
With the advent of newer radiation techniques offering the ability for more localized radiation, it has been postulated that the occurrence of long-term side effects may decrease 29 . Nevertheless, long-term follow-up studies comparing older and newer radiation techniques are scarce 36 .
Because associations have been observed between higher IGF-1 levels and neoplasms, concerns have been raised about the potential oncogenic effect of GH-RT 37 . Although a full evaluation of this particular subject is beyond the scope of the present study, only three patients had received GH-RT prior to the development of a secondary intracranial tumor. Additionally, in a previous study, we did not find increased malignancy-related mortality in patients receiving GH-RT 25 , which is in agreement with other published data 38 .
Radiotherapy was not associated with mortality in the present study. Several studies have described increased mortality, mainly due to cerebrovascular diseases, in patients with hypopituitarism and/or PAs 15, 27, 32 . Comparison and interpretation of these studies, however, are complicated due to a wide variation in underlying disorders, treatment modalities, definitions, and duration of follow-up.
In a previous study from our registry, cerebrovascular mortality was significantly higher in IRR patients than in non-IRR patients receiving GH-RT 25 . All-cause mortality, however, did not differ between the two groups. This was also observed in the present study, in which we further analyzed potential influencing factors. After adjustment for age and other relevant confounders, including GH-RT, mortality was similar in IRR and non-IRR patients. This is in agreement with the findings by Sattler et al. 20 . Tomlinson et al. observed no effect of radiotherapy on mortality in a subanalysis with hypopituitary patients with a NFPA 27 .
A major strength of the present study includes the large cohort of NFPA patients, which enables comparison of IRR and non-IRR patients. In addition, thorough registration of events was ensured through (bi-) annual monitoring by specially trained nurses. However, it should be taken into account that, because the database was set up around the start of GH-RT, events before that date could have been underreported, even though data were also retrospectively collected. Also, the follow-up time differed between IRR and non-IRR patients because the indication for radiotherapy gradually declined through the years due to improvements in imaging and surgical techniques 16 .
This may have influenced the results. However, differences in follow-up time have also been observed in other published series comparing IRR and non-IRR patients 16, 20, 33 .
Details on stroke type and radiotherapy protocol were unfortunately not available in the present study.
The clinical decision to administer radiotherapy was not randomized in this observational study. However, due to the nature of NFPAs and the long-term follow-up required to detect long-term adverse events, randomized controlled trials may not be feasible. Finally, it should be kept in mind that only NFPA patients with severe GHD, and not those with an intact GH-IGF-1 axis, were included in the study population.
Nevertheless, as such, the study population provides useful information.
In conclusion, in this large cohort of NFPA patients, a threefold increased risk of CVE was demonstrated in IRR men compared with non-IRR men but not in women.
Furthermore, secondary intracranial tumors were not encountered more often in IRR patients than in non-IRR patients, and radiotherapy was not associated with increased mortality. Although possible causative underlying mechanisms remain to be elucidated, these data suggest that pituitary radiotherapy may increase the risk of CVE, especially in men. The benefits of radiotherapy should be carefully balanced against potential long-term side effects. Continuous surveillance of IRR patients is required. Further prospective research is needed to evaluate long-term effects and safety of radiotherapy in NFPA patients.
